Preclinical studies suggest that retatrutide might influence being overweight-involved most cancers progression. In a study led by Marathe et al., retatrutide-induced weight loss reduced tumor engraftment, delayed tumor onset, and significantly attenuated tumor advancement in pancreatic and lung most cancers versions, with better tumor suppression